Memory Pharmaceuticals (nasdaq: MEMY - news - people ) has a nicotinic receptor drug for Alzheimer's in midstage trials that is probably a year behind Targacept, figures Lazard (nyse: LAZ - news - people ) Capital Markets analyst Terence Flynn.
FORBES: The Nicotine Cure